الفهرس 
Novel biomarkers in multiple sclerosis
AbstractOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Background: Multiple Sclerosis (MS) is a debilitating disease of the central nervous system (CNS) pathologically characterized by myelin loss and axonal degeneration. Despite multiple diagnostic tests, MS remains a clinical diagnosis with supportive paraclinical evidence. Objective: To measure the serum level of glutamate and nitric oxide in MS patients in different disease phases and controls to explore the possibility of using them as a biomarker for disease activity and relapses. Design/Methods: This study was carried out on 70 MS patients , diagnosed according to revised McDonald criteria 2010,from MS unit at Kasr Al-Ainy hospital, Cairo University, and 20 age and sex matched controls. Subjects were divided into group 1: Thirty MS patients without history of relapse or corticosteroids intake within the last 3 months, The patients were further subdivided into group 1a patient with active disease (n=16) and group 1b patient without active disease (n=14) group 2: Forty MS patients with history of relapse within the last 30 day, without History of regular corticosteroid intake in the last 3 months prior to the relapse, group 3: Twenty healthy control. Serum level of glutamate and Nitric oxide were tested in all groups